Antiviral humoral immunity: Enemy or ally of viral immunotherapy?

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Oncolytic viruses are emerging as potent cancer immunotherapy agents, selectively targeting cancer cells.
• While direct cell lysis was a known mechanism, the role of antitumor immunity in oncolytic virotherapy is increasingly recognized.
• The contribution of humoral immunity, including neutralizing antibodies, to oncolytic virus efficacy is not fully understood.

Purpose of the Study:

• To review the current understanding of humoral immune responses in oncolytic virotherapy.
• To discuss how antiviral immunity influences the effectiveness of oncolytic viruses.
• To explore factors affecting the humoral immune response to oncolytic viruses and their therapeutic outcomes.

Main Methods:

• Literature review of preclinical and clinical studies on oncolytic virotherapy and antiviral immunity.
• Analysis of emerging data on the role of neutralizing antibodies and other humoral factors.
• Discussion of factors influencing humoral immune responses, such as administration route and tumor characteristics.

Main Results:

• Emerging data suggest antiviral immunity contributes significantly to oncolytic virus efficacy.
• Evidence challenges the dogma that neutralizing antibodies solely inhibit oncolytic virotherapy.
• Factors like administration route, tumor vascularization, and viral mechanisms influence humoral immunity's role.

Conclusions:

• Humoral immunity plays a complex role in oncolytic virotherapy, with potential for both inhibition and enhancement.
• Further research is needed to understand regulatory B cells, immunoglobulin isotypes, and Fc-mediated functions.
• Appropriate preclinical models are crucial for accurately predicting oncolytic virotherapy outcomes in clinical settings.